Treatment options for transplant-ineligible patients with multiple myeloma

KarMMA-2 cohort 2b update: ide-cel for transplant-ineligible patients with high-risk myelomaПодробнее

IMROZ- IsaRVd vs RVd in Newly Diagnosed Transplant Ineligible MM | Thierry Facon, MD | EHA 2024Подробнее

Quadruplet regimens for patients with transplant-ineligible multiple myelomaПодробнее

Multiple Myeloma | What Clinicians Want to Know About Anti-CD38 Antibodies in the Management of M...Подробнее

Multiple Myeloma and D-Rd vs. V-Rd TreatmentПодробнее

Comparing TTNT or death between front-line DRd and VRd in transplant-ineligible multiple myelomaПодробнее

ASH23: Frontline Treatment DRd vs. VRd for Transplant-Ineligible Myeloma Patients | Doris Hansen, MDПодробнее

Current Treatment Paradigm for Newly Diagnosed Multiple Myeloma.Подробнее

Frontline and CAR-T Cell Therapy for Multiple Myeloma | Xavier Leleu, MD, MSc, PhD | EHA 2024Подробнее

Discussing Treatment Algorithm for Newly Diagnosed Multiple Myeloma with Dr. Caitlin CostelloПодробнее

Multiple Myeloma - 2023 Best of Hematology ConferenceПодробнее

Multiple Myeloma: What New Patients NEED TO KNOW | The Patient StoryПодробнее

Individualizing treatment in transplant-eligible & transplant-ineligible NDMMПодробнее

Newest Immunotherapies for Blood Cancer! What to Know about Bispecifics & CAR T-Cell TherapyПодробнее

Multiple Myeloma: Should I Get Vaccinated? | The Patient StoryПодробнее

Top Doctor & Patient Talk Game Changing Cancer Treatments: How Close is a Cure? (Multiple Myeloma)Подробнее

Should You Get a Stem Cell Transplant for Multiple Myeloma? What Patients Need to Know!Подробнее

Evolving treatment options in NDMM: transplant-eligible and transplant-ineligible patientsПодробнее

Future Directions for Novel and Next Generation Therapy in Multiple Myeloma | Dana-FarberПодробнее

The Evolution of Systemic Therapy for Newly Diagnosed Multiple Myeloma, Dana-Farber Cancer InstituteПодробнее